ClinicalTrials.gg
TerminatedNCT00678587ELEVATEUpdated Oct 12, 2018Results posted

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

A Phase 3 interventional study of Eltrombopag and Placebo in Non-alcoholic Steatohepatitis, Chronic Liver Disease and HCV, sponsored by GlaxoSmithKline. Terminated at 107 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Why this study was terminated
GSK decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
40th of 460
292 · median 56
Started
2008
with 16 others
Phase 3
29 of 547
7 open now
Registered
35th of 547
by date
Lead sponsor
8 of 547
GlaxoSmithKline

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 40th largest by enrollment of the 460 interventional ones that give a count, is one of 17 that started in 2008, is one of 29 in phase 3, and was the 35th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive procedures. The clinical benefit of eltrombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an invasive procedure. In addition, bleeding events will be monitored during this time. The number of transfusions, safety events and medical resource utilisation will be monitored during this time and for up to 30 days after undergoing an invasive procedure to help further evaluate clinical benefit.

03

Conditions studied

  • Non-alcoholic Steatohepatitis
  • Chronic Liver Disease
  • HCV
  • NASH - Nonalcoholic Steatohepatitis
  • HIV Infection
  • Thrombocytopenia
  • Hepatitis C Virus
  • HBV
  • Human Immunodeficiency Virus
  • Liver Diseases
  • Hepatitis B Virus

Keywords

  • elective invasive procedure.
  • platelet transfusion
  • chronic liver disease-related thrombocytopenia
  • platelets
  • thrombopoietin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, 18 years of age or more with chronic liver disease.
  • score of 12 or less.
  • Model of End Stage Liver Disease (MELD) score of 24 or less.
  • Subjects who, in the opinion of the investigator, are appropriate candidates to undergo an elective invasive procedure and who require a transfusion to manage the risk of bleeding associated with the procedure.
  • A baseline platelet count \<50,000/µL.
  • A baseline serum sodium level >130mEq/L.
  • concentration >8g/dL stable for at least one month.
  • A female is eligible to enter and participate in the study if she is of:

Non- (i.e., physiologically incapable of becoming pregnant) including any female who:

  • Has had a hysterectomy
  • Has had a bilateral oophorectomy (ovariectomy)
  • Has had a bilateral tubal ligation
  • Is (demonstrate total cessation of menses for greater than one year)

Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of product and uses one of the following acceptable methods of :

  • Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical study, and for 28 days after completion or premature discontinuation from the study to account for the elimination of the study drug (minimum of 5 half-lives).
  • Any intrauterine device (IUD) with a documented failure rate of less than 1% per year.
  • Double-barrier contraception (condom with spermicidal jelly, or diaphragm with spermicide).
  • Male partner who is sterile (diagnosed by a qualified medical professional) prior to the female subject's study entry and is the sole sexual partner for that female.
  • Oral contraceptive (either combined or progesterone only).
  • Any other contraceptive method with a documented failure rate of \<1% per year.
  • Subject has no physical limitation to ingest and retain oral medication.
  • Subject is able to understand and comply with protocol requirements and instructions and is likely to complete the study as planned.
  • Subject is able to provide signed and dated written .
  • In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known , intolerance or allergy to any of the ingredients in eltrombopag tablets.
  • Evidence of portal vein thrombosis on abdominal imaging (ultrasound with Doppler or appropriate MRI/CT imaging techniques) within 3 months of study start.
  • History of arterial or venous thrombosis, including Budd-Chiari Syndrome, AND ≥ two of the following risk factors: hereditary thrombophilic disorders (e.g. Factor V Leiden, ATIII deficiency, etc.), hormone replacement therapy, systemic therapy (containing oestrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension or cancer.
  • Any disease condition associated with current active WHO Grade 3 or 4 bleeding.
  • Active infection requiring systemic antibiotic therapy. Prophylactic use of antibiotics is permitted.
  • Pregnant or nursing women.
  • Treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • History of agglutination abnormality that prevents reliable measurement of platelet counts.
  • History of porphyria.
  • Previous participation in TPL104054.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
292 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    placebo, once daily, oral

    Drug: Placebo

  • Active comparator
    Active

    75 mg, once daily, oral

    Drug: Eltrombopag

Interventions

  • 75 mg, once daily, oral

  • DrugPlacebo

    placebo, once daily, oral

06

What researchers measure

Primary outcomes

  1. Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures

    A platelet transfusion was given if the platelet count was \<50 giga (10\^9) per liter (Gi/L) before the procedure. A platelet transfusion was not given if the platelet count was \>80 Gi/L (based on a primary endpoint of success). For participants with platelet counts between 50 Gi/L and 80 Gi/L, platelet transfusions were administered at the discretion of the investigator and the physician performing the elective invasive procedure.

    Time frame: Prior to, during, and up to seven days following elective invasive procedures (Study Days 16-19); therefore, this covers a time period from Baseline to Day 26

Secondary outcomes

  1. Number of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures

    The WHO Bleeding Scale was used to assess bleeding during the study. The range of possible scores is 0 to 4. Grade 0 is no bleeding; Grade 1 is petechiae (small \[1-2 millimeter\] red or purple spot on the body, caused by a minor hemorrhage); Grade 2 is mild blood loss; Grade 3 is gross blood loss (requiring a transfusion; and Grade 4 is debilitating blood loss (retinal or cerebral associated with fatality).

    Time frame: Prior to, during, and up to 7 days following elective invasive procedures (Study Days 16-19); therefore, this covers a time period from Baseline to Day 26

  2. Number of Participants With the Indicated Number of Platelet Transfusions Administered

    Platelet transfusion use was documented at every visit throughout the study from screening until the 4-week (30-day) post-procedure follow-up visit or at the time of participant withdrawal from the study.

    Time frame: Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26

  3. Median Platelet Count at Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 Day Follow-up; Early Withdrawal; and Maximum Post-baseline

    Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).

    Time frame: Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 day follow-up; early withdrawal; and maximum post-baseline

  4. Number of Participants With the Indicated Platelet Count at Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 Day Follow-up (FU); and Maximum Post-baseline

    Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).

    Time frame: Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 day follow-up; and maximum post-baseline

  5. Number of Participants Experiencing an Adverse Event (AEs) and Serious Adverse Event (SAEs) Within the Indicated Category

    An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect or an ocular event of clinical concern. Medical or scientific judgement is exercised in deciding whether reporting is appropriate in other situations.

    Time frame: Screening to Procedure +30 day follow-up or early withdrawal

  6. Number of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant

    Time frame: Screening to Procedure +30 day follow-up or early withdrawal

  7. Number of Participants With the Indicated Event Relating to Vision

    The progression of pre-existing cataracts was measured by the use of slit lamp examination. Decrease in visual acuity is defined as the loss of 3 or more lines of visual acuity in either eye (0.3 log minimal angle of resolution \[logMAR\], 15 letters on the standard Early Treatment Diabetic Retinopathy Study chart).

    Time frame: Screening or Baseline and at End of Study (Procedure +30 day follow-up or withdrawal visit)

  8. Number of Participants With Renal Function Abnormality

    Renal function abnormality was defined by threshold values for: serum creatinine: change from baseline of \>=0.3 and \<0.5 milligrams (mg)/deciliter (dL) (\>=26.6 and \<44.3 micromoles \[umol\]/L) or change from baseline of \>=0.5 mg/dL (\>=44.3 umol/L); microscopic urine analysis: cellular casts pathologic (as defined by local standards of microscopic urine analysis); urine protein/creatinine ratio (UP/CR): \>0.5 mg/mg; Glomerular Filtration Rate (GFR) as determined by the Cockcroft-Gault formula and urine dipstick test.

    Time frame: Screening to Procedure +30 day follow-up or early withdrawal

  9. Number of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results

    A 12-lead ECG was obtained in duplicate at screening, baseline, Day 15, and withdrawal from the study. Participants rested supine for 5 minutes before the 12-lead ECG was recorded. A 30 second rhythm strip was obtained, and the ECG was calibrated, labelled, and initialled by the person performing the recording. A written, interpretive assessment detailing clinical significance was produced, dated, and signed off by the physician at the site.

    Time frame: Screening, Baseline, Day 15, and Withdrawal

  10. Pharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau)

    AUC(0-tau) is the area under a concentration versus time curve between dose interval following repeat dosing. It is a measure of systemic drug exposure.

    Time frame: Day 14

  11. Pharmacokinetics (PK) of Eltrombopag, Cmax

    Cmax is the steady state peak plasma concentration of a drug observed after its administration.

    Time frame: Day 14

  12. Pharmacokinetics (PK) of Eltrombopag, t1/2

    t1/2 is the half life of a drug based on its terminal phase. Half life is defined as the time necessary to halve the plasma concentration.

    Time frame: Day 14

  13. Pharmacokinetics (PK) of Eltrombopag, CL/F

    CL/F is the apparent plasma clearance, where CL is an estimate of the total body clearance, and F is the fraction of dose absorbed. Total clearance is the volume of blood cleared of the drug by the various elimination processes (metabolism and excretion) per unit time.

    Time frame: Day 14

  14. Mean Number of Days Spent in the Hospital

    The number of days spent in the hospital was analyzed as an indication of medical resource utilization throughout the study.

    Time frame: Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26

  15. Mean Number of Unscheduled Office Visits, Unscheduled Laboratory Tests, and Unscheduled Procedures

    The number of unscheduled events was analyzed as an indication of medical resource utilization throughout the study.

    Time frame: Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26

07

Results

Posted Nov 7, 2010

Participant flow

Participant flow — Overall Study
MilestonePlaceboEltrombopag 75 mg
Started147145
Completed127127
Not completed2018
Withdrew: Adverse event33
Withdrew: Lack of efficacy10
Withdrew: Protocol violation21
Withdrew: Study closed/terminated10
Withdrew: Lost to follow-up35
Withdrew: Investigator discretion26
Withdrew: Withdrew consent83

Outcome measures

PrimaryNumber of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures

A platelet transfusion was given if the platelet count was \<50 giga (10\^9) per liter (Gi/L) before the procedure. A platelet transfusion was not given if the platelet count was \>80 Gi/L (based on a primary endpoint of success). For participants with platelet counts between 50 Gi/L and 80 Gi/L, platelet transfusions were administered at the discretion of the investigator and the physician performing the elective invasive procedure.

Time frame:
Prior to, during, and up to seven days following elective invasive procedures (Study Days 16-19); therefore, this covers a time period from Baseline to Day 26
Reported as:
Number · participants
Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures
participantsPlaceboEltrombopag 75 mg
Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures28104
Statistical analysis
  • Placebo vs Eltrombopag 75 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Absolute difference in proportions: 52.8 · 95% CI 43.2 to 62.4
SecondaryNumber of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures

The WHO Bleeding Scale was used to assess bleeding during the study. The range of possible scores is 0 to 4. Grade 0 is no bleeding; Grade 1 is petechiae (small \[1-2 millimeter\] red or purple spot on the body, caused by a minor hemorrhage); Grade 2 is mild blood loss; Grade 3 is gross blood loss (requiring a transfusion; and Grade 4 is debilitating blood loss (retinal or cerebral associated with fatality).

Time frame:
Prior to, during, and up to 7 days following elective invasive procedures (Study Days 16-19); therefore, this covers a time period from Baseline to Day 26
Reported as:
Number · participants
Number of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures
participantsPlaceboEltrombopag 75 mg
Number of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures3425
Statistical analysis
  • Placebo vs Eltrombopag 75 mg · Risk difference (rd): -5.9 · 95% CI -15.1 to 3.3
SecondaryNumber of Participants With the Indicated Number of Platelet Transfusions Administered

Platelet transfusion use was documented at every visit throughout the study from screening until the 4-week (30-day) post-procedure follow-up visit or at the time of participant withdrawal from the study.

Time frame:
Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26
Reported as:
Number · participants
Number of Participants With the Indicated Number of Platelet Transfusions Administered
participantsPlaceboEltrombopag 75 mg
030106
19324
231
320
430
500
610
Died/withdrew prior to any platelet transfusions1514
Statistical analysis
  • Placebo vs Eltrombopag 75 mg · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryMedian Platelet Count at Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 Day Follow-up; Early Withdrawal; and Maximum Post-baseline

Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).

Time frame:
Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 day follow-up; early withdrawal; and maximum post-baseline
Reported as:
Median · Gi/L
Median Platelet Count at Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 Day Follow-up; Early Withdrawal; and Maximum Post-baseline
Gi/LPlaceboEltrombopag 75 mg
Screening, n=147, 14540.0 (8 to 70)40.0 (3 to 55)
Day 1, n=145, 14140.0 (8 to 222)40.0 (12 to 62)
Day 8, n=139, 13441.0 (6 to 190)58.5 (20 to 337)
Day 15, n=132, 13139.0 (6 to 200)103.0 (25 to 397)
Days 16-19, n=50, 4941.5 (18 to 250)107.0 (30 to 406)
Procedure + 7 day follow-up, n=128, 12544.0 (17 to 150)148 (30 to 493)
Procedure + 14 day follow-up, n=116, 12547.5 (13 to 370)110 (18 to 805)
Procedure + 21 day follow-up, n=120, 11744.5 (11 to 200)62.0 (15 to 967)
Procedure + 30 day follow-up, n=125, 12740.0 (10 to 200)50.0 (14 to 999)
Early withdrawal, n=9, 840.0 (11 to 195)41.0 (32 to 140)
Maximum post-baseline, n=144, 14053.0 (16 to 370)152 (32 to 999)
SecondaryNumber of Participants With the Indicated Platelet Count at Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 Day Follow-up (FU); and Maximum Post-baseline

Procedure +7 = Days 23-26; +14 = Days 30-33; +21 = Days 37-40; +30 = Days 46-49. Early withdrawal can occur at any time. Maximum post-baseline refers to any time point listed above for which the maximum value was reached (therefore this time point is variable).

Time frame:
Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 day follow-up; and maximum post-baseline
Reported as:
Number · participants
Number of Participants With the Indicated Platelet Count at Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 Day Follow-up (FU); and Maximum Post-baseline
participantsPlaceboEltrombopag 75 mg
Screening, <50 Gi/L, n=147, 145133136
Screening, >=50-<=80 Gi/L, n=147, 145148
Screening, >80-<=200 Gi/L, n=147, 14500
Screening, >200-<=400 Gi/L, n=147, 14500
Screening, >400 Gi/L, n=147, 14500
Day 8, <50 Gi/L, n=139, 1359848
Day 8, >=50-<=80 Gi/L, n=139, 1353450
Day 8, >80-<=200 Gi/L, n=139, 135733
Day 8, >200-<=400 Gi/L, n=139, 13503
Day 8, >400 Gi/L, n=139, 13500
Day 15, <50 Gi/L, n=132, 1319814
Day 15, >=50-<=80 Gi/L, n=132, 1312631
Day 15, >80-<=200 Gi/L, n=132, 131867
Day 15, >200-<=400 Gi/L, n=132, 131019
Day 15, >400 Gi/L, n=132, 13100
Procedure + 7 Day FU, <50 Gi/L, n=128, 1267811
Procedure + 7 Day FU, >=50-<=80 Gi/L, n=128, 1263820
Procedure + 7 Day FU, >80-<=200 Gi/L, n=128, 1261260
Procedure + 7 Day FU, >200-<=400 Gi/L, n=128, 126030
Procedure + 7 Day FU, >400 Gi/L, n=128, 12604
Procedure + 14 Day FU, <50 Gi/L, n=117, 1256322
Procedure + 14 Day FU, >=50-<=80 Gi/L, n=117, 1254021
Procedure + 14 Day FU, >80-<=200 Gi/L, n=117, 1251162
Procedure + 14 Day FU, >200-<=400 Gi/L, n=117, 125217
Procedure + 14 Day FU, >400 Gi/L, n=117, 12503
Procedure + 21 Day FU, <50 Gi/L, n=121, 1178038
Procedure + 21 Day FU, >=50-<=80 Gi/L, n=121, 1173033
Procedure + 21 Day FU, >80-<=200 Gi/L, n=121, 1171038
Procedure + 21 Day FU, >200-<=400 Gi/L, n=121, 11707
Procedure + 21 Day FU, >400 Gi/L, n=121, 11701
Maximum Post-Baseline, <50 Gi/L, n=144, 1406011
Maximum Post-Baseline, >=50-<=80 Gi/L, n=144, 1405323
Maximum Post-Baseline, >80-<=200 Gi/L, n=144, 1402862
Maximum Post-Baseline, >200-<=400 Gi/L, n=144, 140337
Maximum Post-Baseline, >400 Gi/L, n=144, 14007
SecondaryNumber of Participants Experiencing an Adverse Event (AEs) and Serious Adverse Event (SAEs) Within the Indicated Category

An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect or an ocular event of clinical concern. Medical or scientific judgement is exercised in deciding whether reporting is appropriate in other situations.

Time frame:
Screening to Procedure +30 day follow-up or early withdrawal
Reported as:
Number · participants
Number of Participants Experiencing an Adverse Event (AEs) and Serious Adverse Event (SAEs) Within the Indicated Category
participantsPlaceboEltrombopag 75 mg
AEs during study8579
Drug-related AEs in >1 participant1531
Throboembolic AEs26
Bleeding AEs2519
Hepatobiliary AEs1624
Malignancy AEs11
Renal AEs42
Death on study23
SAEs in >1 participant during study1719
Drug-related SAEs in >1 participant49
Thrombocytopenia11
Progression of pre-existing cataract n=145,14320
Incident cataract develpment n=145,14324
Decrease in visual acuity n=121,1241921
Renal function abnormality n=145,1432728
Clinically significant change in ECG n=128,13001
SecondaryNumber of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant
Time frame:
Screening to Procedure +30 day follow-up or early withdrawal
Reported as:
Number · participants
Number of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant
participantsPlaceboEltrombopag 75 mg
Number of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant49
SecondaryNumber of Participants With the Indicated Event Relating to Vision

The progression of pre-existing cataracts was measured by the use of slit lamp examination. Decrease in visual acuity is defined as the loss of 3 or more lines of visual acuity in either eye (0.3 log minimal angle of resolution \[logMAR\], 15 letters on the standard Early Treatment Diabetic Retinopathy Study chart).

Time frame:
Screening or Baseline and at End of Study (Procedure +30 day follow-up or withdrawal visit)
Reported as:
Number · participants
Number of Participants With the Indicated Event Relating to Vision
participantsPlaceboEltrombopag 75 mg
Progression of pre-existing cataract, n=145, 14320
Cataract development, n=145, 14324
Decrease in visual acuity, n=121, 1241921
SecondaryNumber of Participants With Renal Function Abnormality

Renal function abnormality was defined by threshold values for: serum creatinine: change from baseline of \>=0.3 and \<0.5 milligrams (mg)/deciliter (dL) (\>=26.6 and \<44.3 micromoles \[umol\]/L) or change from baseline of \>=0.5 mg/dL (\>=44.3 umol/L); microscopic urine analysis: cellular casts pathologic (as defined by local standards of microscopic urine analysis); urine protein/creatinine ratio (UP/CR): \>0.5 mg/mg; Glomerular Filtration Rate (GFR) as determined by the Cockcroft-Gault formula and urine dipstick test.

Time frame:
Screening to Procedure +30 day follow-up or early withdrawal
Reported as:
Number · participants
Number of Participants With Renal Function Abnormality
participantsPlaceboEltrombopag 75 mg
Number of Participants With Renal Function Abnormality2728
SecondaryNumber of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results

A 12-lead ECG was obtained in duplicate at screening, baseline, Day 15, and withdrawal from the study. Participants rested supine for 5 minutes before the 12-lead ECG was recorded. A 30 second rhythm strip was obtained, and the ECG was calibrated, labelled, and initialled by the person performing the recording. A written, interpretive assessment detailing clinical significance was produced, dated, and signed off by the physician at the site.

Time frame:
Screening, Baseline, Day 15, and Withdrawal
Reported as:
Number · participants
Number of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results
participantsPlaceboEltrombopag 75 mg
Number of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results01
SecondaryPharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau)

AUC(0-tau) is the area under a concentration versus time curve between dose interval following repeat dosing. It is a measure of systemic drug exposure.

Time frame:
Day 14
Reported as:
Geometric mean · hour*micrograms (ug)/milliliter (mL)
Pharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau)
hour*micrograms (ug)/milliliter (mL)Eltrombopag 75 mg
Pharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau)250 (211 to 296)
SecondaryPharmacokinetics (PK) of Eltrombopag, Cmax

Cmax is the steady state peak plasma concentration of a drug observed after its administration.

Time frame:
Day 14
Reported as:
Geometric mean · ug/mL
Pharmacokinetics (PK) of Eltrombopag, Cmax
ug/mLEltrombopag 75 mg
Pharmacokinetics (PK) of Eltrombopag, Cmax11.6 (9.8 to 13.6)
SecondaryPharmacokinetics (PK) of Eltrombopag, t1/2

t1/2 is the half life of a drug based on its terminal phase. Half life is defined as the time necessary to halve the plasma concentration.

Time frame:
Day 14
Reported as:
Geometric mean · hours
Pharmacokinetics (PK) of Eltrombopag, t1/2
hoursEltrombopag 75 mg
Pharmacokinetics (PK) of Eltrombopag, t1/270.3 (60.7 to 81.5)
SecondaryPharmacokinetics (PK) of Eltrombopag, CL/F

CL/F is the apparent plasma clearance, where CL is an estimate of the total body clearance, and F is the fraction of dose absorbed. Total clearance is the volume of blood cleared of the drug by the various elimination processes (metabolism and excretion) per unit time.

Time frame:
Day 14
Reported as:
Geometric mean · Liters/hour
Pharmacokinetics (PK) of Eltrombopag, CL/F
Liters/hourEltrombopag 75 mg
Pharmacokinetics (PK) of Eltrombopag, CL/F0.30 (0.25 to 0.36)
SecondaryMean Number of Days Spent in the Hospital

The number of days spent in the hospital was analyzed as an indication of medical resource utilization throughout the study.

Time frame:
Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26
Reported as:
Mean · days
Mean Number of Days Spent in the Hospital
daysPlaceboEltrombopag 75 mg
Mean Number of Days Spent in the Hospital1.3 ± 3.771.7 ± 6.43
SecondaryMean Number of Unscheduled Office Visits, Unscheduled Laboratory Tests, and Unscheduled Procedures

The number of unscheduled events was analyzed as an indication of medical resource utilization throughout the study.

Time frame:
Prior to, during, and up to 4 weeks (30 days) following elective invasive procedures (Days 16-19); therefore, this covers a time period from Baseline to Day 26
Reported as:
Mean · unscheduled events
Mean Number of Unscheduled Office Visits, Unscheduled Laboratory Tests, and Unscheduled Procedures
unscheduled eventsPlaceboEltrombopag 75 mg
Unscheduled office visits0.8 ± 1.641.0 ± 2.91
Unscheduled laboratory tests1.1 ± 3.781.8 ± 5.67
Unscheduled procedures0.3 ± 0.810.4 ± 1.65

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) with an onset on or after the start date of study medication were collected until the end of the study (up to the end of Week 7).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—17/145 (11.7%)35/145 (24.1%)
Eltrombopag 75 mg—19/143 (13.3%)40/143 (28%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventPlaceboEltrombopag 75 mg
Portal vein thrombosisHepatobiliary disorders2/1454/143
Mesenteric vein thrombosisGastrointestinal disorders1/1453/143
CataractEye disorders3/1451/143
Hepatic encephalopathyNervous system disorders3/1452/143
SepsisInfections and infestations0/1452/143
Rectal haemorrhageGastrointestinal disorders2/1450/143
Abdominal painGastrointestinal disorders0/1451/143
Appendix disorderGastrointestinal disorders0/1451/143
AscitesGastrointestinal disorders0/1451/143
Ileus paralyticGastrointestinal disorders0/1451/143
Most frequent other events
Most frequent other events
EventPlaceboEltrombopag 75 mg
HeadacheNervous system disorders6/14511/143
PyrexiaGeneral disorders10/1458/143
Abdominal painGastrointestinal disorders7/1457/143
NauseaGastrointestinal disorders7/1457/143
DiarrhoeaGastrointestinal disorders5/1457/143

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboEltrombopag 75 mgTotal
Mean53.5 ± 11.7851.6 ± 11.0452.5 ± 11.44
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEltrombopag 75 mgTotal
Female5549104
Male9296188
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEltrombopag 75 mgTotal
White9385178
Central/South Asian Heritage334174
Japanese/East Asian/South East Asian Heritage191433
African American/African Heritage246
Native Hawaiian/Other Pacific Islander and White011
Number of participants categorized into the indicated Child-Pugh (CP) Class
Number of participants categorized into the indicated Child-Pugh (CP) Class(participants)PlaceboEltrombopag 75 mgTotal
Child-Pugh Class A5968127
Child-Pugh Class B6457121
Child-Pugh Class C171027
Model for End-Stage Liver Disease (MELD) Score at Baseline
Model for End-Stage Liver Disease (MELD) Score at Baseline(scores on a scale)PlaceboEltrombopag 75 mgTotal
Median12 (6 to 25)12 (6 to 24)12 (6 to 25)
08

Study locations

107 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294-0005, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85259, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205-7199, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    San Diego, California 92103-8707, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Denver, Colorado 80262, United States
  • GSK Investigational Site
    Washington, District of Columbia 20307, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Baltimore, Maryland 21202, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Valhalla, New York 10595, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28203, United States
  • GSK Investigational Site
    Durham, North Carolina 27715, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033-0850, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Nashville, Tennessee 37232, United States
  • GSK Investigational Site
    Dallas, Texas 75235, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Falls Church, Virginia 22046, United States
  • GSK Investigational Site
    Richmond, Virginia 23249, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    Capital Fefderal, Buenos Aires, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1181ACI, Argentina
  • GSK Investigational Site
    Derqui, Pilar, Buenos Aires B1629AHJ, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2002KDR, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, 1264, Argentina
  • GSK Investigational Site
    Brussels, 1070, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M6H 3M1, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3J4, Canada
  • GSK Investigational Site
    Clermont Ferrand Cédex 1, 63058, France
  • GSK Investigational Site
    Lyon Cedex 02, 69288, France
  • GSK Investigational Site
    Lyon, 69437, France
  • GSK Investigational Site
    Marseille, 13385, France
  • GSK Investigational Site
    Montpellier, 34295, France
  • GSK Investigational Site
    Nice, 06202, France
  • GSK Investigational Site
    Paris Cedex 12, 75571, France
  • GSK Investigational Site
    Paris Cedex 13, 75651, France
  • GSK Investigational Site
    Paris, 75014, France
  • GSK Investigational Site
    Villejuif, 94804, France
  • GSK Investigational Site
    Jaipur, 302004, India
  • GSK Investigational Site
    Mumbai, 400 016, India
  • GSK Investigational Site
    Mumbai, 400020, India
  • GSK Investigational Site
    Avellino, Campania 83100, Italy
  • GSK Investigational Site
    Napoli, Campania 80123, Italy
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Roma, Lazio 00133, Italy
  • GSK Investigational Site
    Roma, Lazio 00168, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20122, Italy
  • GSK Investigational Site
    Milano, Lombardia 20132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20162, Italy
  • GSK Investigational Site
    Torino, Piemonte 10126, Italy
  • GSK Investigational Site
    Bari, Puglia 70124, Italy
  • GSK Investigational Site
    San Giovanni Rotondo (FG), Puglia 71013, Italy
  • GSK Investigational Site
    Palermo, Sicilia 90127, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Busan, 614-735, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400-711, Korea, Republic of
  • GSK Investigational Site
    Seoul, 120-752, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    Lahore, 54000, Pakistan
  • GSK Investigational Site
    Lahore, 54600, Pakistan
  • GSK Investigational Site
    Chorzow, 41-500, Poland
  • GSK Investigational Site
    Lubin, 59-301, Poland
  • GSK Investigational Site
    Slupsk, 76-200, Poland
  • GSK Investigational Site
    Warszawa, 01-201, Poland
  • GSK Investigational Site
    Wroclaw, 50-367, Poland
  • GSK Investigational Site
    Ekaterinburg, 620102, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 194044, Russian Federation
  • GSK Investigational Site
    Samara, 443011, Russian Federation
  • GSK Investigational Site
    Smolensk, 214006, Russian Federation
  • GSK Investigational Site
    Barakaldo, 48903, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Hospitalet de Llobregat, 08907, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    Oviedo, 33006, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Valencia, 46009, Spain

Showing the first 100 of 107 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012 Aug 23;367(8):716-24. doi: 10.1056/NEJMoa1110709. PubMed 22913681 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 1 month after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2008
First posted
May 15, 2008
Start
Jun 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results delay requested
Aug 12, 2010
Results first posted
Nov 7, 2010
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00678587
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 15, 2008
Start date
Jun 2008
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Nov 7, 2010
Last update
Oct 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion